Objective: There is a paucity of randomized clinical trials (RCTs) for adolescents with bulimia nervosa (BN). Prior studies suggest cognitive-behavioral therapy adapted for adolescents (CBT-A) and family-based treatment for adolescent bulimia nervosa (FBT-BN) could be effective for this patient population. The objective of this study was to compare the relative efficacy of these 2 specific therapies, FBT-BN and CBT-A. In addition, a smaller participant group was randomized to a nonspecific treatment (supportive psychotherapy [SPT]), whose data were to be used if there were no differences between FBT-BN and CBT-A at end of treatment.
B
ulimia nervosa (BN) is a serious eating disorder among adolescents, with a prevalence of more than 1% and another 2% to 3% presenting with clinically significant bulimic symptoms.
1,2 BN among adolescents is associated with medical sequelae such as hypokalemia, esophageal tears, gastric disturbances, dehydration, orthostasis, cardiac arrhythmias, and death. 3 Psychiatric complications include depression, personality disorders, anxiety, and substance use disorders. 4, 5 Several randomized controlled trials (RCTs) have now tested a range of treatments for adults with BN. [6] [7] [8] [9] Overall, results suggest that cognitive-behavioral therapy (CBT) is the most efficacious approach and therefore the first-line treatment for adults with this disorder. 6 However, despite the fact that bulimic behaviors typically have an onset during adolescence, there is a paucity of studies evaluating treatments in this age group. Several case series of bulimic adolescents suggest that family therapy 10, 11 or CBT adapted for adolescents (CBT-A) 12 is feasible and leads to clinical improvements. Two relatively modest RCTs for adolescents with BN have been published with somewhat equivocal results. 13, 14 Schmidt et al 13 found no difference at the end of treatment (EOT) or at 6-month follow-up in rates of achieving abstinence from binge eating and purging between adolescents randomized to either a self-help version of CBT or family therapy (about 40% in both groups at follow-up), although some advantages were achieved for CBT in terms of secondary outcomes. Le Grange et al.
14 found that participants randomized to receive a specific form of family therapy (family-based treatment for adolescent bulimia nervosa [FBT-BN]) achieved higher abstinence rates at EOT (40%) compared to those who received a nonspecific therapy (supportive psychotherapy [SPT] ; 20%), but abstinence rates for both groups dropped at the 6-month follow-up mark. Taken together, these studies suggest that both FBT-BN and CBT-A are likely effective treatments for adolescents with BN.
FBT-BN and CBT-A are conceptually distinct. FBT-BN encourages parental control and management of eating disorder behaviors with no emphasis on changing pathological thinking related to shape and weight; CBT-A is primarily an individual therapy that focuses on reducing dieting and changing distorted behaviors and cognitions related to shape and weight. FBT has a substantial evidence base documenting its effectiveness for adolescent anorexia nervosa (AN), [15] [16] [17] whereas CBT has a preponderance of evidence supporting its use in adults with BN. [6] [7] [8] [9] Hence, an adequately powered RCT of these 2 specific approaches for adolescents with BN could shed light not only on which treatment is more effective but potentially on the benefits of these different strategies on differing patient groups (moderators). Based on the evidence supporting FBT for adolescents with AN, we hypothesized that FBT-BN would be superior to CBT-A for this age group, but expected that age, individual psychopathology, and family pathology would moderate the achievement of abstinence.
Although our design was powered for a comparison between 2 specific treatments (FBT-BN and CBT-A), as a condition of funding, a third, nonspecific treatment, namely supportive psychotherapy (SPT), was added to the design to allow an exploratory comparison of whether there were no differential treatment effects between the specific treatments by the EOT. Although this third condition was included in the RCT, recruitment to this arm was designed to be at a lower rate and was not sufficiently powered for a statistically valid comparison with the other treatments. Instead, if there were no difference at the EOT between FBT-BN and CBT-A, a comparison to SPT would generate hypotheses for future studies.
METHOD Study Design
In this 2-site (The University of Chicago and Stanford University) study, 130 participants were randomized to FBT-BN, CBT-A, or SPT. To limit the number of participants in the nonspecific therapy (SPT) group, 18 given our primary hypothesis, randomization was done in unequal proportions of 2:2:1 for FBT-BN : CBT-A : SPT. Randomization, with no stratification on baseline variables, was done by staff at the Data Coordinating Center (DCC), but separately for each site. Treatment conditions were randomly ordered before consecutive identification numbers were assigned. Families were notified of treatment assignment before Session 1, with participants considered entered when told their treatment allocation. Therapists, comprising 6 PhD psychologists, 1 social worker, and 1 child psychiatrist, all with prior experience treating eating disorders in adolescents, conducted either FBT-BN or CBT-A, but not both, to limit potential therapist confounds in the specific treatments. However, all therapists also treated patients using the nonspecific treatment, SPT. Therapist training in these 3 manualized treatments was conducted at two 2-day workshops. The first of these workshops was held before recruitment, and the second workshop, 6 months after the first participants were randomized. Psychotherapy experts and authors of this report (D.L.G. for FBT-BN, J.D.L. and W.S.A. for CBT-A, and D.L.G. for SPT) conducted the initial training as well as subsequent weekly supervision. All therapists were required to satisfactorily treat a minimum of 3 pilot cases before being assigned randomized cases. Study treatment was provided in eating disorder clinics for children and adolescents located at each of the participating sites. The institutional review boards at both The University of Chicago and Stanford University approved this study protocol.
Sample Characteristics
Recruitment was conducted from January 2009 through December 2012 by local advertising to clinicians, organizations, and clinics treating eating disorders. Telephone screening to determine eligibility allowed for 145 participants (49% of 296) to be invited for an assessment interview ( Figure 1 ). The study was described to participants and parents at the time of interview to obtain written informed consent (assent for adolescents <18 years of age) before assessments were conducted. Participants, male and female, were eligible if between ages 12 and 18 years, living with at least 1 parent, and meeting criteria for DSM-IV BN or partial BN (binge eating and purging once or more per week over 6 months), 19 or expected body weight (EBW) >85%. 20 Family, for the purposes of this study, included members of the participant's household, that is, at least 1 parent or adult guardian. Single, divorced, or step-parent families were eligible for the study. Participants on a stable dose of medication for 2 months for a co-morbid psychiatric treatment, while meeting study entry criteria, were eligible. Participants were excluded if they had a current psychotic illness or other mental illness requiring hospitalization, bipolar I disorder, depression with active suicidal thoughts and behavior, associated physical illness that necessitated hospitalization, current dependence on drugs or alcohol, current diagnosis of AN or weight less than 85% EBW, physical conditions known to influence eating or weight, previous FBT-BN, CBT, or SPT for BN, or were married or emancipated minors. All study participants were required to be available for the duration of 6 months' treatment provided in this study.
The primary aim of this study was to compare 2 specific treatments (FBT-BN and CBT-A) in adolescents with clinically significant bulimic behaviors. A total of 130 participants agreed to randomization (97% of eligible participants). One individual was later withdrawn because the participant was found not to meet study eligibility.
Participant Safety
A site-specific child and adolescent psychiatrist blind to the participant's psychological treatment managed co-morbid psychiatric conditions requiring medications. Other psychiatric co-morbidities were managed by study therapists in the context of the therapies being delivered for BN. Participants were withdrawn when clinical severity of other psychiatric problems outweighed the benefits of continuing assigned study treatment, or psychiatric hospitalization exceeded 72 hours, or medical hospitalization associated with BN exceeded 21 days in total, or more than 2 such hospitalizations. Participants withdrawn from the protocol were referred for appropriate treatment outside the study. The therapists and site-specific principal investigator provided emergency coverage of patients. Initial and ongoing medical oversight was provided to ensure medical stability for outpatient treatment. A site-specific pediatrician blinded to patient assignment provided this oversight and determined medical instability that would warrant hospitalization based on published criteria. 21 
Interventions
All treatments were delivered within 18 sessions over a period of 6 months.
Specific Interventions. FBT-BN is derived from the manualized approach used with adolescent AN, 22 although it differs in some key areas. 23 For instance, FBT-BN assumes that the secrecy, shame, and dysfunctional eating patterns associated with BN negatively affect adolescent development and confuse and disempower parents. The primary treatment strategy is to engage the adolescent in a more collaborative relationship with parents in promoting behavioral change. To target BN behaviors, FBT-BN uses 3 stages over 6 months.
CBT-A is a manualized treatment adapted for adolescents with BN. 12 It is derived from CBT for adult BN originally developed by Fairburn et al. 24 Similar to CBT for adults with BN, CBT-A follows 3 stages over 6 months. Major modifications for adolescents are as follows: increased contact of therapist with adolescent in early treatment to promote therapeutic alliance; collateral sessions with parents to educate parents about BN and to elicit their support of treatment using CBT; use of concrete examples to illustrate points; and exploration of adolescent developmental issues (e.g., autonomy concerns) in the context of BN.
Nonspecific Intervention. SPT is a manualized treatment adapted for adolescent BN.
14 It is derived from a version for adults with BN, 18 which in turn was derived from earlier work with BN by Fairburn et al. 25 It contains no putative active therapeutic ingredients, for example, stimulus-control or problem-solving techniques, or instruction on changes in diet and eating patterns. Therefore, SPT is nondirective in nature and does not overlap with any specific factors or active agents that are typical of FBT-BN or CBT-A. SPT consists of 3 phases that are conducted over 6 months.
Assessments
Assessments were conducted at 4 time points: baseline, end-oftreatment (EOT), and 6-and 12-month follow-up. Independent and trained assessors who were not involved in treatment and intended to be blinded to treatment assignment conducted all assessments. The primary outcome in this study was abstinence from binge eating and purging episodes (any compensatory behaviors) assessed using the Eating Disorder Examination (EDE) 26 at EOT. The a priori definition of abstinence rate was the proportion of participants who achieved abstinence from binge eating and purging for 4 weeks before the assessment. Previous studies suggest that abstinence defined this way is the best predictor of enduring treatment effects in BN. 6 The EDE is a standardized investigator-based interview that measures the severity of the characteristic psychopathology of eating disorders. It is a measure of present state and is exclusively concerned with the preceding 4 weeks. Total binge eating episodes, total purge episodes, subjective binge eating episodes, percent EBW, age, gender, duration of illness, minority, pretreatment medication, intact family, family income, parental education, and average parental age were assessed. The following measures were used to assess other potential moderators of outcome: Beck Depression Inventory (BDI), 27 Family Environment Scale (FES), 28 Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), 29 Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS), 30 Schedule for Affective Disorders and Schizophrenia for School-Aged Children (6-18 years)-Present and Lifetime Version (K-SADS-PL), 31 and the Rosenberg Self-Esteem Scale (RSES).
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Statistical Analysis
To estimate longitudinal trends and treatment effects based on these trends, we used longitudinal mixed-effects modeling 33, 34 with repeated assessments at baseline, EOT (28 weeks), and 6-month (54 weeks) and 12-month (80 weeks) follow-up. Specifically, we used a random intercept model with individually varying time scores (assessment weeks from baseline). We included all randomized individuals (intention-to-treat principle: FBT-BN, n ¼ 51; CBT-A, n ¼ 58) in the analyses if data from at least 1 of the 4 assessments was available. Missing data were treated as missing at random (MAR) conditional on observed information using maximum likelihood estimation, 35 which is the standard assumption that underlies contemporary approaches to missing data. All analyses of primary and secondary outcomes were conducted, taking into account site and site-by-treatment interaction effects. Mplus (V 7.3) 36 was used to conduct maximum likelihood estimation for all longitudinal mixed-effects analyses.
The study was powered to test the primary hypothesis that rate of abstinence at EOT would be different between FBT-BN and CBT-A. Using a medium effect size derived from preliminary studies 13, 14 (success rate difference ¼ 0.25), estimated power is 0.85 (a ¼ 0.05, 2-sided). For the primary outcome, abstinence (1 ¼ yes; 0 ¼ no), we conducted mixed-effects growth modeling using 3 repeated measures (EOT and 6-and 12-month follow-up), as there was no variation in the data at baseline (i.e., no baseline abstinence). We used a random intercept model with individually varying time scores (assessment weeks from baseline), treating abstinence status as a binary outcome. In addition to the standard MAR, we used an alternative missing data assumption as a way of sensitivity analysis. In this alternative assumption, we assumed that none of the early dropouts (FBT-B, n ¼ 5; CBT-A, n ¼ 6) would be abstinent at EOT, as early treatment dropouts are more unlikely to recover. The analyses based on 2 different missing data assumptions resulted in the same conclusions (comparable effect sizes with almost identical p values). Given the similar results, we report here only the results based on the standard MAR assumption.
For the exploratory moderator analysis, we incorporated the MacArthur framework 37, 38 in the longitudinal modeling framework. We also examined 5 secondary outcomes (BDI, EDE Global, CY-BOCS Total, YBC Total, and %EBW) by conducting standard mixed-effects analyses using all 4 repeated assessments. All 109 participants randomized to FBT-BN or CBT-A were included, as they had available data for at least 1 of the 4 assessment time points. We used piecewise growth modeling (baseline to EOT and EOT to 12-month follow-up) to accommodate considerable nonlinear trends over time.
As our primary comparison between the 2 specific treatments (FBT-BN and CBT-A) rendered a significant finding as hypothesized, and in keeping with our original study aims, we did not conduct further comparisons involving the third treatment group (SPT). Participant characteristics as well as outcome data for SPT are provided in Tables S1 and S2, available online.
RESULTS
Participant Characteristics
The mean age of participants (N ¼ 109) was 15. Most participants (94%) were female, with a mean duration of illness of 18.9 months (SD ¼ 17.2 months). Of the participants, 67% (n ¼ 73) reported a current comorbid psychiatric disorder, and 9% (n ¼ 10) were taking psychotropic medications at baseline. A total of 58% (n ¼ 63) were from intact families; 46% (n ¼ 50) were ethnic minorities (self-reported); and 33% (n ¼ 34) had been hospitalized for BN, or medical complications associated with BN, before randomization. Table 1 provides descriptive statistics by center and treatment.
Treatment Delivery and Study Retention
Treatment time did not differ between FBT-BN and CBT-A (average, 13.6 versus 14.7 sessions, respectively). The Spearman correlation between number of sessions and abstinence rates at EOT was not significant. Study dropout (i.e., failure to complete study assessment) was 10% at EOT, 38% at 6-month follow-up, and 36% at 12-month follow-up (Figure 1 ). At 6-month follow-up, there was a site difference, with Chicago having a dropout rate of 43.6% (n ¼ 24) compared to a rate of 31.5% (n ¼ 17) at Stanford.
Primary and Secondary Outcomes
The results of the longitudinal analysis of the primary outcome (abstinence) are summarized in Table 2 . We conducted our analyses taking into account site and site-bytreatment interaction effects, although none of them were found to be significant. The results reported in Table 2 Figure 2 , based on longitudinal mixed-effects modeling, show the overall abstinence rates (i.e., percentage who reached abstinence) in the 2 treatment conditions that change across 4 assessment points.
The results of our secondary outcome analyses are summarized in Table 2 . Among the 5 secondary outcomes we examined (BDI, EDE Global, CY-BOCS Total, YBC Total, and %EBW), using mixed-effect modeling, the only outcome that showed a significant group difference was BDI. 
Treatment Effect Moderators of Primary Outcome
We examined 29 baseline variables as potential moderators of treatment effect (see Measures), using the same longitudinal mixed-effect model used for the primary outcome analysis. Among the 29 variables considered, only FES Conflict (p ¼ .048) was identified as a treatment effect moderator. 37, 38 Participants with a lower FES Conflict score responded better to FBT-BN compared to CBT-A (Figure 3 ).
Nonspecific Predictors of Primary Outcome
Gender (p ¼ .043), YBC Total (p ¼ .008), FES Cohesion (p < .001), intellectual-cultural orientation (p ¼ .015), activerecreational orientation (p ¼ .003), and organization (p ¼ .032) at baseline emerged as nonspecific predictors of abstinence at EOT. Regardless of treatment type, males, individuals with lower YBC Total, and those scoring higher on these FES subscales all showed higher abstinence rates at EOT.
Hospitalization During Treatment Phase
There were no site differences in terms of hospital rates. However, more participants were hospitalized in CBT-A (n ¼ 12, 21%) than in FBT-BN (n ¼ 1, 2%) (W 1 ¼ 5.9, p ¼ .015). Four CBT-A participants were hospitalized more than once. In all, 75% (9 of 12) of CBT-A and 100% (1 of 1) of the first FBT-BN hospitalizations were in the first 8 weeks of treatment. Half of all hospitalizations were for psychiatric reasons, that is, mostly mood disorder related (30% of all hospitalizations), with concomitant suicidality (20% of all hospitalizations). Nonpsychiatric admissions were due mostly to medical instability (50% of all hospitalizations), mostly bradycardia (30% of all hospitalizations).
Treatment During Follow-Up
There were no differences in treatment use between the 2 treatments during the follow-up period (n ¼ 72). In FBT-BN, 7 participants (20%) received individual therapy, 4 (11%) medical management, 1 (3%) group therapy, and 4 (11%) nutritional counseling, and 3 (9%) were hospitalized. In CBT-A, 9 participants (32%) received individual therapy, 6 (16%) medical management, 3 (8%) group therapy, FIGURE 2 Estimated trajectories of abstinence rates using longitudinal mixed effects modeling. Note: Curves presented here are overall curves and therefore may not exactly agree with the main effect estimates presented in Table 2 that are averaged across 2 sites; observed n ¼ 51 family-based therapy for bulimia nervosa (FBT-BN) and n ¼ 58 cognitivebehavioral therapy adapted for adolescents (CBT-A) at baseline; both n ¼ 43 at end of treatment (EOT); both n ¼ 34 at 6-month follow-up (FU); n ¼ 29 FBT-BN; and n ¼ 41 CBT-A at 12-month follow-up. and 1 (3%) nutritional counseling, and 2 (5%) were hospitalized.
DISCUSSION
The results of this study support our primary hypothesis that FBT-BN would be superior to CBT-A for adolescents with BN at the EOT and 6-month follow-up; however, abstinence rates no longer differed statistically by 12-month follow-up. Of our proposed moderators, family pathology (FES Conflict) emerged as a significant moderator of treatment effect. That is, participants with lower FES Conflict scores responded better to FBT-BN compared to CBT-A, but there was no differentiation between these 2 treatments in families with higher levels of FES Conflict scores. Perhaps similar to earlier findings in adolescent anorexia nervosa, 39 FBT-BN might not necessarily be the treatment of choice for high-conflict families. Of the secondary outcomes, only BDI showed a significant difference, with those receiving FBT-BN demonstrating greater improvements. Our findings underscore those of the prior RCTs for adolescents with BN, 13, 14 demonstrating that both family therapy and CBT are viable treatment options for this patient population, but suggest that abstinence occurs more rapidly in FBT-BN and with fewer hospitalizations than in CBT-A.
Strengths of this study include a relatively large sample size, manualized treatments, trained and skilled therapists, ongoing supervision by experts, and independent assessors using standardized outcome measures. Treatment attrition and study dropout during treatment were relatively low. Among the limitations of our study, however, is the loss of follow-up data by 12 months, which would need to be addressed in the design of future studies of this population. Recruitment and treatment of participants were conducted at specialist university treatment sites, which may limit the generalizability of the findings. Furthermore, both study sites are known for research in FBT, and this perception could have affected our results. However, therapists at both sites have a long history, training, and practice of CBT for adolescents with BN. Therapists treated participants in only 1 of the 2 specific conditions; 1 of the principal investigators (J.D.L.) is the author of the only previously published treatment study of CBT for this patient population, and another (W.S.A.) has been an investigator in numerous studies of CBT for adults with BN (see, for example, Agras et al. 6 ). Moreover, additional efforts were made to limit any bias through use of an independent DCC, as well as cross-site training and supervision procedures. That said, these findings would be strengthened if replicated by other centers not involved in the development of either FBT or CBT.
Findings from the present study, taken together with those from previous studies of adolescents with BN, 13, 14 suggest that FBT-BN is likely a better initial treatment option compared to CBT-A for those adolescents with clinically significant bulimic behaviors. FBT-BN leads to quicker and higher sustained abstinence rates that are maintained up to 12 months posttreatment associated with medium effect sizes, as well as significantly less hospitalization. It appears that, similar to their adolescent peers with AN, adolescents with BN can benefit from an approach that actively involves their families in the treatment process. However, given that there were no statistical differences between these 2 treatments at 12 months posttreatment, CBT-A remains a viable alternative treatment for this patient population, especially for those families who would prefer a largely individual treatment or when there is no family available to be of help. Unfortunately, our exploratory moderator analysis did not identify a patient group that showed differentially favorable response to CBT-A. Larger studies with a greater adolescent age and diagnostic range might be needed to identify such moderating groups.
There clearly remains a need for ongoing development of innovative treatments for this patient population, given that, in this study, less than half of patients were recovered at 12-month follow-up, whether in FBT-BN or in CBT-A. Future studies might consider using CBT-E, adapted for adolescents, as this approach is the latest iteration of CBT for eating disorders that is now available. Alternatively, the utility of integrative cognitive-affective therapy 40 or interpersonal therapy, 6 if adapted for adolescents, or a stepped-care 
